Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Annals of HematologyOpen Access

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HNHenrik NiklasABAnna BoldSVSimon Völkl

Discussion

Loading...

Member takes

Overview

Case report demonstrates deep response to sequential BCMA CAR T-cell therapy in advanced multiple myeloma, suggesting retreatment feasibility after CELMoD bridging.

Key Points

  • To evaluate the feasibility and therapeutic efficacy of a second BCMA-targeted CAR T-cell infusion following CELMoD-based bridging therapy in relapsed multiple myeloma.
  • Treated a 58-year-old male with high-risk IgA kappa multiple myeloma who relapsed following sixth-line idecabtagene vicleucel therapy.
  • Confirmed retained BCMA expression using whole genome sequencing prior to re-treatment.
  • Administered bridging therapy consisting of mezigdomide, carfilzomib, and dexamethasone before infusing ciltacabtagene autoleucel.
  • Observed marked early reductions in serum IgA and free kappa light chains accompanied by robust CAR T-cell expansion.
  • Recorded manageable toxicity comprising grade II cytokine release syndrome and prolonged cytopenias, without immune effector cell-associated neurotoxicity.

Cite This Study

Niklas et al. (2026) studied this question.

synapsesocial.com/papers/6aabb69c5f706d05830e52ddhttps://doi.org/10.1007/s00277-026-07278-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential BCMA CAR T-cell therapy in refractory multiple myeloma2025 · 12 citations
  2. 2Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.2017 · 67 citations
  3. 3Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma: Potential Benefits and Key Challenges to Becoming a Standard Treatment2026
  4. 4The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma2025 · 2 citations
  5. 5CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma2025 · 9 citations